Botulinum Toxin to Improve Results in Epicanthoplasty
Status:
Unknown status
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
Medial epicanthal fold is a common skin fold in the inner part of the eye in more than 50%
Asia population, giving the illusion of a shorter palpebral fissure length and a wider
intercanthal distance. Currently, various epicanthoplasty techniques have been well described
to correct epicanthus fold. However, hypertrophic scarring after epicanthoplasty remains a
clinical challenge, which seems inevitable and may leading to unpleasing supratarsal crease,
recurrence of medial epicanthus fold, even obvious scar formation. Botulinum toxin type A
(BTX-A) is widely used for facial rejuvenation and many other medical indications. It is a
potent neurotoxin that indirectly blocks neuromuscular transmission and leads to functional
denervation of striated muscle for 2 to 6 months after injection. Recently, experimental
study and clinical trails have revealed that BTX-A can inhibit the growth of fibroblasts
derived from hypertrophic scars and influenced the expression of transforming growth
factor-β1. Therefore, we hypothesized that BTX-A can improve hypertrophic scarring after
epicanthoplasty through release orbicularis oculi muscle tension, inhibit fibroblast growth,
and reduce collagen production. The main aim of this trail is to evaluate the efficiency of
BTX-A injection on improving hypertrophic scaring after epicanthoplasty.
Phase:
Phase 3
Details
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A onabotulinumtoxinA